CureVac N.V.

-0.29 (-0.52%)
Products, Regulatory

CureVac's CVnCoV Phase 2B/3 Study Data Published In Preprints With The Lancet

Published: 08/31/2021 11:06 GMT
CureVac N.V. (CVAC) - Cvncov Phase 2b/3 Study Data Published in Preprints With the Lancet.
Significant Protection Was Demonstrated Among Participants in Age Group of 18 to 60, With an Efficacy of 53% Against Disease of Any Severity and Across All 15 Identified Strains.
Protection Against Moderate to Severe Disease for This Age Group Was Calculated to Be 77%.
In Same Age Group, Cvncov Provided 100% Protection Against Hospitalization Or Death.
Submission of Comprehensive Clinical Data Packages to Ema is Ongoing As Part of Rolling Submission Initiated in February 2021 and is Expected to Be Finalized Toward End of Q3 of 2021.